Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02220738 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
A Phase 1 study, sponsored by AbbVie.
- Terminated
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT02220738 is a Phase 1 study that was terminated before completion, run by AbbVie. The registered enrollment target is 19 participants.
The verdict
NCT02220738, a Phase 1 study, was terminated before completion, sponsored by AbbVie.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
This study is designed to evaluate the safety, tolerability and pharmacokinetics of multiple doses of ABT-957 in subjects with mild to moderate Alzheimer's disease.
Interventions
- DRUG ABT-957
- OTHER Placebo for ABT-957
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2014-09 |
| Est. Completion | 2016-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02220738
The ClinicalTrials.gov registry entry for NCT02220738 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ABT-957 is the first listed.
NCT02220738 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02220738 about?
NCT02220738 is a clinical study titled "Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors". This study is designed to evaluate the safety, tolerability and pharmacokinetics of multiple doses of ABT-957 in subjects with mild to moderate Alzheimer's disease.
What is the current status of trial NCT02220738?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2014-09. Estimated completion is 2016-03.
What interventions are being tested in trial NCT02220738?
The interventions under investigation include: ABT-957 (DRUG), Placebo for ABT-957 (OTHER).
Who is sponsoring clinical trial NCT02220738?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.